Join to View Full Profile
619 19th St SBirmingham, AL 35249
Phone+1 205-934-4011
Dr. Khalil is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 2017 - 2020
HCA Florida JFK Hospital/University of Miami Miller School of Medicine GME ConsortiumResidency, Internal Medicine, 2014 - 2017
American University of Beirut Faculty of MedicineClass of 2012
Certifications & Licensure
AL State Medical License 2020 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study Start of enrollment: 2023 Mar 14
- Study With Various Immunotherapy Treatments in Participants With Lung Cancer Start of enrollment: 2023 Feb 21
Publications & Presentations
PubMed
- HSR25-148: The State of Lung Cancer in Alabama.Ellen McNeeley, Elizabeth Dickson-Gavney, Sanad Alhushki, Sameer Deshmukh, Ann Steagall
Journal of the National Comprehensive Cancer Network. 2025-03-28 - 5 citationsRandomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.Aaron S Mansfield, Jun Vivien Yin, Penelope Bradbury, David J Kwiatkowski, Shiven Patel
Lung Cancer. 2024-09-01 - 2 citationsTalazoparib in Patients With Solid Tumors With/Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study.Gordan Srkalovic, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Eugene R Ahn
JCO Precision Oncology. 2024-06-01
Press Mentions
FDA Approval, Big News Complicate EGFR-Mutated NSCLC DecisionsFebruary 24th, 2025- FDA Approvals Create “Difficult Decisions” in Early-Stage Resectable NSCLCAugust 26th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
